Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with <i>EGFR</i> G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review

Epidermal growth factor receptor (<i>EGFR</i>) tyrosine kinase inhibitors (TKIs) are effective in non-small-cell lung cancer (NSCLC) with sensitizing mutations. However, patients with uncommon <i>EGFR</i> mutations show variable responses, and resistance often develops. The C797S mutation is a commo...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Wenting Lu, Jiayi Sun, Yawan Jing, Jing Xu, Chengming Huang, Yi Deng, Panwen Tian, Yalun Li
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	MDPI AG 2025-03-01
Reeks:	Current Oncology
Onderwerpen:	NSCLC <i>EGFR</i> mutation <i>EGFR</i>-TKI osimertinib gefitinib bevacizumab
Online toegang:	https://www.mdpi.com/1718-7729/32/4/201
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!